Rhythm Pharmaceuticals Inc

Company Profile

• Business description

  Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

• Contact

  222 Berkeley Street
  12th Floor
  BostonMA02116
  USA

  T: +1 857 264-4280

  E: [email protected]

  https://www.rhythmtx.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  414